Nashville — The Healing NET Foundation, in partnership with the Association for Value-Based Cancer Care (AVBCC) a non-profit managed by The Lynx Group, is convening an inaugural international summit of leading physicians and bench researchers which begins this week in Beaver Creek, Colorado, to focus on a rare cancer that is not widely recognized in medical circles. Celebrities such as Steve Jobs and Dave Thomas are among the thousands of individuals who have been diagnosed with neuroendocrine (NET) cancer in the United States.
NASHVILLE — Diagnosis and treatment of Neuroendocrine (NET) Cancers will be debated Feb. 24- 26 when physicians and bench researchers from more than 30 research hospitals across the United States and Europe gather in Beaver Creek, Colorado, for a Summit hosted by The Healing NET Foundation in partnership with the Association for Value-Based Cancer Care.
IMBRUVICA™ Approved For Previously Treated Chronic Lymphocytic Leukemia; Immediately Available Through Onco360®
New York – February 12, 2014 – Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, is proud to be part of the limited Specialty Pharmacy Network of IMBRUVICA™ (ibrutinib). IMBRUVICA™ is now also indicated for the treatment of patients with Chronic Lymphocytic Leukemia (CLL), who have received at least one prior therapy. This indication is based on overall response rate. An improvement in survival or disease-related symptoms has not been established.
New Orleans, LA—Important breakthrough results that have the potential to significantly affect the management of patients with leukemia, lymphoma, and multiple myeloma were presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition, which was held December 6-10, 2013.
PharMerica and Onco360 Finalize Strategic Investment; Establish First National Oncology Pharmacy and Care Management Platform
LOUISVILLE, Ky. and NEW YORK – December 9, 2013 – PharMerica Corporation’s (NYSE: PMC), a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, and Onco360, the largest independent provider of oncology pharmacy services in the United States, today announced that the companies have entered into a definitive agreement under which PharMerica has acquired a significant minority stake of Onco360.
Chicago, IL—Sorafenib (Nexavar) has become the first drug in years to prove effective in the treatment of differentiated thyroid cancer (DTC) that has become resistant to radioactive iodine, according to phase 3 study results that were reported at the 2013 American Society of Clinical Oncology annual meeting.
Chicago, IL—Inappropriate deviation from evidence-based standards of care for cancer raises costs in excess of $25,000 per patient, stated Arlene A. Forastiere, MD, Senior Vice President of Medical Affairs at eviti, Inc, Philadelphia, PA, in a poster presented at the 2013 American Society of Clinical Oncology annual meeting.
In Dr Forastiere’s review of oncology treatment plans for 2544 consecutive patients, approximately 25% of the patients had treatment plans that did not conform to evidence-based standards.
Page 1 of 17
Results 1 - 10 of 162
Results 1 - 10 of 162